Should Growth Investors Buy This Genetic Diagnostics Stock?
Aside from getting the entry point right on an investment, being a growth investor arguably boils down to two key factors: picking a well-run company, and one that's operating in an industry set to experience tremendous growth.
Given the increasing emphasis on early diagnosis and treatment of diseases, market research firm Global Market Insights anticipates the global genetic-testing market will grow 11.6% annually from $14.9 billion last year to $31.9 billion by 2027. As a quality, midsize genetic-diagnostics company, Veracyte (NASDAQ: VCYT) is large enough to continue innovating, yet nimble enough to adapt to a rapidly changing industry.
What makes Veracyte a great business? And should you buy the stock at its current valuation? Let's dig in to answer these questions.
Source Fool.com
